Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805-Reference-Cited by-同舟云学术

Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805

Published:2022-05-10 Issue:12 Volume:82 Page:1176-1185
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Morgans Alicia K.¹,Chen Yu‐Hui²,Jarrard David F.³^ORCID,Carducci Michael⁴,Liu Glenn³,Eisenberger Mario⁴,Plimack Elizabeth R.⁵,Bryce Alan⁶^ORCID,Garcia Jorge A.⁷,Dreicer Robert⁸,Vogelzang Nicholas J.⁹,Picus Joel¹⁰,Shevrin Daniel¹¹¹²,Hussain Maha¹,DiPaola Robert S.¹³,Cella David¹,Sweeney Christopher J.¹⁴^ORCID,

Affiliation:

1. Department of Medicine (Hematology and Oncology) Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago Illinois USA

2. Department of Biostatistics and Computational Biology ECOG‐ACRIN Cancer Research Group Dana‐Farber Cancer Institute Boston Massachusetts USA

3. Departments of Urology and Medicine, UW Carbone Cancer Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

4. Department of Oncology Johns Hopkins University Baltimore Maryland USA

5. Department of Hematology and Oncology, Fox Chase Cancer Center Temple University Health System Philadelphia Pennsylvania USA

6. Division of Hematology and Medical Oncology Mayo Clinic Scottsdale Arizona USA

7. Department of Medicine, Case Comprehensive Cancer Center, Seidman Cancer Center University Hospitals Case Medical Center Cleveland Ohio USA

8. Division of Hematology and Oncology University of Virginia Cancer Center Charlottesville Virginia USA

9. Nevada Cancer Research Foundation Comprehensive Cancer Centers of Nevada Las Vegas Nevada USA

10. Division of Medical Oncology, Siteman Cancer Center Washington University School of Medicine St. Louis Missouri USA

11. General Oncology NorthShore University HealthSystem Evanston Illinois USA

12. Cleveland Clinic Taussig Cancer Institute Cleveland Ohio USA

13. College of Medicine University of Kentucky College of Medicine Lexington Kentucky USA

14. Medical Oncology Harvard Medical School, Dana Farber Cancer Institute Boston Massachusetts USA

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24369

Reference34 articles.

1. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

3. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy

4. The association of weight gain during adulthood with prostate cancer incidence and survival: A population-based cohort

5. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of Life Determinants in Patients with Metastatic Prostate Cancer: Insights from a Cross-Sectional Questionnaire-Based Study;Current Oncology;2024-08-26

2. Identifying Suitable Patients for Overcoming Androgen Deprivation Monotherapy in De Novo Metastatic Hormone-Sensitive Prostate Cancer;Journal of Personalized Medicine;2024-05-13

3. Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI;JCO Precision Oncology;2024-05

4. About metformin and its action on the mitochondrial respiratory chain in prostate cancer;Translational Andrology and Urology;2024-05

5. Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide;The Prostate;2023-11